
















doi:10.101Polymorphisms in CCR6 Are Associated with Chronic
Graft-versus-Host Disease and Invasive Fungal
Disease in Matched-Related Hematopoietic
Stem Cell Transplantation
Kelly Broen,1 Anniek B. van derWaart,1 Annelies Greupink-Draaisma,1 JuliaMetzig,1 Ton Feuth,2
Nicolaas P.M. Schaap,3 NicoleM. A. Blijlevens,3Walter J. F. M. van der Velden,3 Harry Dolstra1Graft-versus-host disease (GVHD) and fungal infections are frequent complications after allogeneic hemato-
poietic stem cell transplantation (HSCT). Single nucleotide polymorphisms (SNPs) in genes of the immune
system can influence the inflammatory cascade and T cell–driven alloimmune reactions after HSCT, and
thus increasing the incidence of GVHD and infectious complications. Here, we investigated the effect of
SNPs in IL-23R and CCR6 on posttransplantation outcome in 161 recipients of partially T cell–depleted
HSCT. Remarkably, IL-23R SNPs were not associated with clinical outcome, but we found that disparities
in the CCR6 tagSNP rs2301436 and SNP rs3093023 are independently associated with the occurrence of
chronic GVHD (cGVHD) and invasive fungal disease. In multivariate analysis, patients receiving a transplant
from a homozygous rs2301436 G allele donor showed less cGVHD (odds ratio [OR]: 0.16; P 5 .002), as
was the case for a homozygous donor rs3093023 G allele (OR: 0.24; P5 .005). In parallel, the GG genotype
at rs2301436 in donorswas associatedwith a higher incidence of invasive fungal disease at day 100 afterHSCT
(OR: 3.59; P 5 .008). This study shows that CCR6 SNPs can be used to predict clinical outcome, and that
polymorphisms in the CCR6 gene may influence T cell–mediated immune reactions after HSCT.
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Graft-versus-host disease (GVHD) and fungal
infections remain major causes of morbidity and mor-
tality in allogeneic hematopoietic stem cell transplan-
tation (HSCT) [1]. The pathophysiology of acute
GVHD (aGVHD) is a multistep process involving tis-
sue damage and cytokine release induced by pretrans-
plantation conditioning followed by alloreactive T cellDepartment of LaboratoryMedicine, Hematology Labo-
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6/j.bbmt.2011.07.004expansion, trafficking, and destruction of target tissues
by effector T cells [2]. The pathogenesis of chronic
GVHD (cGVHD) is even more complex and has not
yet been fully defined [3,4]. Recent insights have
challenged the paradigm of GVHD being almost
exclusively a Th1-mediated immune disorder, given
that studies have shown a role for Th17 responses in
both aGVHD and cGVHD. Similarly, new insights
have emerged in the field of antifungal immunity
showing a pronounced role of Th17 responses, includ-
ing release of the cytokines interleukin (IL)-17 and IL-
22, in fungal defenses complementing Th1 responses.
The IL-23/Th17 pathway is a new player at the
crossroads of innate and adaptive immunity [5].
Th17 cells are induced by the release of IL-1b, IL-6,
and transforming growth factor b from antigen-
presenting cells (APCs), and further expansion is en-
hanced by IL-23, although controversy exists because
of the considerable differences seen in animal and hu-
man studies [6]. Th17 CD41 T cells are characterized
by expression of retinoid-related orphan receptor and
the chemokine receptors CCR4 and CCR6 [7].
CCR6 expression recently has been shown to be piv-
otal for Th17 migration to the gut in inflammatory
bowel disease and to the joints in rheumatoid arthritis1443
Table 1. Patient, Donor, and Transplant Characteristics
Characteristic
Age at transplantation, years, median (range) 48 (19-64)
Male sex, n (%) 104 (65)
Sex of patient–donor pair, n (%)
Male–female 42 (26)
Other 119 (74)





Advanced disease stage, n (%) 46 (29)





Stem cell source, n (%)
Bone marrow 62 (39)
Peripheral blood 99 (61)
T cell depletion method, n (%)
Elutriation 44 (27)
CD34 selection 85 (53)
CD3/CD19 depletion 32 (20)
aGVHD, n (%)
Grade II-IV 57 (35)
Grade III-IV 21 (13)
cGVHD, n (%) n 5 142
Limited 16 (10)
Extensive 25 (16)
Invasive fungal disease at day 100, n (%)
Candidemia 16 (10)
Invasive mold disease* 12 (7.5)
Probable/proven 8 (5)
ALL indicates acute lymphocytic leukemia; AML, acute myeloid
leukemia; Bus, busulfan; CLL, chronic lymphocytic leukemia; CML,
chronic myeloid leukemia; Cy, cyclophosphamide; Ida, idarubicin;
MDS, myelodysplastic syndrome; MPS, myeloproliferative syndrome;
NHL, non-Hodgkin lymphoma; TBI, total body irradiation.
*Based on European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and National In-
stitute of Allergy and Infectious Diseases Mycoses Study Group consen-
sus criteria [27].
1444 Biol Blood Marrow Transplant 17:1443-1449, 2011K. Broen et al.[8]. Th17 responses seem to be involved predominantly
in host barrier defenses of the skin and mucosa [9], en-
hancing the innate immunity against extracellular mi-
croorganisms, including fungi, through increased
phagocyte recruitment andproductionof antimicrobial
peptides [10]. However, this pathway is also reportedly
involved in the occurrence of various autoinflammatory
and autoimmune diseases [5,11]. Therefore, the IL-23/
Th17 axis is now being studied with regard to trans-
plantation complications, with an emphasis on
GVHD and infections, although the existence of allor-
eactive Th17 cells also suggests a possible role in graft-
versus-tumor immunity [12-14]. However, most
studies on the IL-23/Th17 axis in GVHD have been
performed in animal models [15,16], and the role of
this axis in human GVHD remains controversial.
Currently, the strongest evidence for a role of the
IL-23/Th17 pathway in human HSCT comes from
the associationbetween anonsynonymous IL-23 recep-
tor (IL-23R) single nucleotide polymorphism (SNP),
rs11209026 (Arg381Gln), in transplant donors and
the incidence of aGVHD [17-19]. This SNP is one of
the now many so-called non-HLA polymorphisms
that have been associated with HSCT outcome [20].
Previously, we reported that performing partial T cell
depletion of donor transplants did not reduce the im-
pact of nucleotide-binding oligomerization domain
SNPs on GVHD and treatment-related mortality
(TRM) in the setting of HLA-matched sibling HSCT
[21]. To investigate whether SNPs in genes more di-
rectly involved inT cell–mediated immunity, including
those involved in the IL-23/Th17 pathway, are more
influenced by the T cell depletion strategy, we per-
formed a retrospective analysis on the impact of
IL-23R polymorphisms (rs11209026 and rs11805303)
in a homogenous cohort of Dutch patients (n 5 161)
undergoing partially T cell–depleted HSCT. In addi-
tion, we studied the impact of a tagSNP for CCR6
(rs2301436) and the CCR6 SNP rs3093023, given that
these SNPs have been associated with the occurrence
of Crohn’s disease and rheumatoid arthritis [22,23].
We found that the IL-23R SNPs were not associ-
ated with the occurrence of GVHD, but that CCR6
tagSNP rs2301436 and SNP rs3093023 were signifi-
cantly associated with less cGVHD. In addition,
CCR6 tagSNP rs2301436 also was associated with
a higher incidence of invasive fungal disease (IFD) af-
ter partially T cell–depleted HSCT.PATIENTS AND METHODS
Patients and Donors
A total of 161 Dutch patients and their donors
were included in the study. All of the patients had
been admitted to our transplantation unit between
1996 and 2009 for an HLA-matched sibling, partiallyT cell–depleted allogeneic HSCT. To obtain the
most homogenous cohort possible, we selected only
those patients who received myeloablative condition-
ing. Of the 161 patients, 124 had received a condition-
ing regimen containing idarubicin. The characteristics
of patients, donors, and HSCT procedures are sum-
marized in Table 1. All patients and donors provided
informed consent for the prospective collection of
data and DNA samples for investigational use. The
study was approved by the RadboudUniversityNijme-
gen Medical Centre’s Institutional Review Board.Treatment Protocol
All patients had been treated according to the same
protocol, as described previously [21]. In brief, the
conditioning regimen consisted of cyclophosphamide
(60 mg/kg for 2 days) in combination with either total
body irradiation (4.5 Gy for 2 days) or busulfan
(4mg/kg for 4 days). Idarubicin (42mg/m2 in 48 hours)
was commonly added to these conditioning regimens
Table 2. Primer Sequences for KASPar Genotyping Assays
SNP Gene Allele Forward Primer (50 to 30) Reverse Primer (50 to 30)
rs11209026 IL-23R a gaaggtgaccaagttcatgctttgattgggatatttaacagatcattcc gtctaaatcagaaaacagaaattctgcaaa
g gaaggtcggagtcaacggattgggatatttaacagatcattccg
rs11805303 IL-23R c gaaggtgaccaagttcatgcttgcaaacagagaactgtttcctc gtcggagctttgtctatttagcaactaat
t gaaggtcggagtcaacggattgcttgcaaacagagaactgtttcctt
rs2301436 tagSNP CCR6 t gaaggtgaccaagttcatgctctgggtaatggaaaagggcttct tctgtttgatataaactaaattgacctctt
c gaaggtcggagtcaacggattctgggtaatggaaaagggcttcc
rs3093023 CCR6 a tattgaaacttcctcaaatttaaaatcacat tttatgcacctcacagtgtctatgcaaat
g attgaaacttcctcaaatttaaaatcacac
Biol Blood Marrow Transplant 17:1443-1449, 2011 1445Impact of CCR6 SNPs on SCT Outcometo reduce the risk of relapse in the setting of partially
T cell–depleted HSCT [24]. On day 0, all patients re-
ceived a stem cell graft containing a median of 3.4 
106 CD341 cells/kg (range, 0.8-11.6  106; bone mar-
row or peripheral blood stem cells) and a median of
0.5  106 CD31 T cells/kg (range, 0.3-0.8  106)
achieved by dosedT cell add-back.GVHDprophylaxis
consisted of cyclosporine A only. Antimicrobial pro-
phylaxis consisted of ciprofloxacin 500 mg twice daily
and valaciclovir 500 mg 3 times daily. Fluconazole
(200 mg/day) was given orally only to those patients
considered colonized by Candida albicans. No mold-
active prophylaxis was provided.
Definition of Outcome Variables
aGVHD was graded according to the criteria of
Przepiorka et al. [25], and cGVHD was classified ac-
cording to the revised Seattle criteria of Lee et al.
[3]. IFD was scored according to the European Orga-
nization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Dis-
eases Mycoses Study Group consensus guidelines
[26], but only probable and proven cases were included
in the analysis. Blood cultures were considered positive
if a microorganism was recovered from 1 or more
bottles, with the exception of coagulase-negative
staphylococci, for which 2 separate positive blood cul-
tures with the same strain were required [27]. Early
Gram-positive bacteremia was defined as bacteremia
with streptococci or staphylococci occurring between
the start of conditioning up to engraftment.
TRM, disease-free survival (DFS), and overall sur-
vival (OS) were defined according to standard criteria.
SNP Genotyping Using the KASPar System
Genotyping was performed for SNPs rs11209026
(Arg381Gln) and rs11805303, which are polymor-
phisms in the IL-23R gene in linkage disequilibrium
with each other [28]. In addition, a tagSNP for
CCR6, rs2301436, was genotyped. This SNP is located
in the FGFR1OP gene, adjacent to CCR6, and has been
associated with Crohn’s disease [23]. SNP rs3093023
is located within the CCR6 gene and has been associ-
ated with rheumatoid arthritis [22]. The HLA-
matchedHSCTdonor–recipient pairs were genotypedby specific KASPar assays (KBioscience, Hoddesdon,
United Kingdom), which are fluorescence-based com-
petitive allele-specific polymerase chain reaction as-
says using nonlabeled primers. Details of the
methodology are available at http://www.kbioscience.
co.uk. Primer sequences are listed in Table 2.
Statistical Analysis
Associations between polymorphisms in recipient
and donor on the one hand and occurrence of
aGVHD, cGVHD, relapse, and IFD before day 100
after HSCT on the other hand were tested using the
chi-square test and the Fisher exact test, as appropri-
ate, and by univariate logistic regression analysis. To
control for possible confounders (eg, aGVHD and
sex combination), multivariate logistic regression anal-
yses was performed. TRM,OS, and time of occurrence
of IFD were analyzed using Kaplan-Meier curves and
the log-rank test.
All statistical analyses were performed using the
cmprsk package of open-source languageR version 2.6.2
(www.r-project.org, R Foundation, Vienna, Austria).
A P value\.05 was considered statistically significant.
RESULTS
SNP Genotype Frequencies
The genotype frequency of the rs11209026,
rs11805303, rs2301436, and rs3093023 polymor-
phisms in both patients and donors are presented in
Table 3. For the IL-23R SNP rs11209026 (ie,
Arg381Gln), virtually no difference was seen between
the GA and GG genotype frequency in donors and pa-
tients. A homogenous AA gene variant of rs11209026
was not detected in any of the donors or patients.Geno-
type frequencies for IL-23R SNP rs11805303, CCR6
tagSNP rs2301436, andCCR6 SNP rs3093023 showed
equal distribution in donors and patients.
SNPs in IL-23R and CCR6 Are Not Associated
with the Incidence of aGVHD
The cumulative incidence of aGVHD grade II-IV
was 35% (57 of 161), with grade III-IV occurring in
13% (21 of 161) (Table 1). IL-23R SNPs rs11209026
and rs11805303 and CCR6 SNPs rs2301436 and
rs3093023 were not associated with the incidence of
Table 3. SNP Genotype Frequencies in Patients and Donors
Variable
Number Evaluable n (%)
Patient Donor Patient Donor
rs11209026 (IL-23R) 160 158
GG 140 (87.5) 140 (88.5)
GA 20 (12.5) 18 (11.5)
rs11805303 (IL-23R) 160 159
CC 79 (49.5) 79 (50)
CT 59 (37) 63 (39.5)
TT 22 (13.5) 17 (10.5)
rs2301436 (tagSNP CCR6) 159 156
AA 32 (20) 29 (18.5)
AG 79 (50) 81 (52)
GG 48 (30) 46 (29.5)
rs3093023 (CCR6) 153 153
AA 24 (16) 30 (20)
AG 72 (47) 68 (44)
GG 57 (37) 55 (36)
1446 Biol Blood Marrow Transplant 17:1443-1449, 2011K. Broen et al.aGVHD (data not shown). Importantly, in contrast to
previous studies [17], patients who received a trans-
plant from a donor with a GA genotype at the IL-23R
SNP rs11209026 (Arg381Gln) did not experience
less aGVHD.Associations between the CCR6 Polymorphisms
and cGVHD
Of the 142 patients at risk for cGVHD, 10% devel-
oped limited cGVHD and 26% developed extensive
cGVHD (Table 1). In univariate analysis, the donor
genotypes of the CCR6 tagSNP rs2301436 and SNP
rs3093023 were significantly associated with the
occurrence of cGVHD (Table 4). The other signifi-
cant variable was previous aGVHD. For tagSNP
rs2301436, the cumulative incidence of cGVHD was
10% for the GG genotype versus 38% and 33% for
the AG and AA genotypes, respectively (P 5 .004)
(Figure 1A and Table 4). In addition, the recipient ge-
notype at tagSNP rs2301436 also was associated withTable 4. Influence of Clinical Factors on Chronic GVHD, Relapse, a
Outcome Parameter Variable
Chronic GVHD Donor rs2301436 GG vs AA/AG 0.1
Recipient rs2301436 AG vs AA/GG 2.8
Donor rs3093023 GG vs AA/AG 0.3
Recipient rs3093023 AG vs AA/GG 2.9
Acute GVHD 4.5
Sex combination 1.5
Relapse Recipient rs2301436 AA vs AG/GG 2.2
Chronic GVHD 0.3
Prophylactic donor lymphocyte infusion 0.6
Diagnosis (CML vs other) 4.9
Conditioning, Ida vs non-Ida 0.4
IFD at day 100 Donor rs2301436 GG vs AA/AG 2.6
Donor rs3093023 GG vs AA/AG 2.1
Acute GVHD 2.0
Conditioning, Ida vs non-Ida 3.1
Dectin-1 Y238X recipient vs wild-type 0.7
CML indicates chronic myeloid leukemia; Ida, idarubicin.cGVHD in univariate analysis, with an incidence of
39% for the heterozygous AG genotype versus 17%
and 20% for the homozygous AA and GG genotypes,
respectively (P 5 .007) (Figure 1B and Table 4). For
CCR6 SNP rs3093023, the cumulative incidence of
cGVHD was 15% for the GG genotype versus 39%
and 32% for the AG and AA genotypes, respectively
(P5 .02) (Figure 1C and Table 4). In addition, the re-
cipient genotype at SNP rs3093023was associatedwith
cGVHD in univariate analysis, with an incidence of
41% for the heterozygous AG genotype versus 19%
for both the homozygous AA and GG genotypes (P 5
.02) (Figure 1D andTable 4). Althoughwe found an as-
sociation between the heterozygous genotype AG in
recipients and cGVHD in both SNPs, these associa-
tions did not seem very plausible, given that compari-
son of the A allele versus G allele frequencies revealed
no risk allele. No significant associations between the
IL-23R SNPs rs11209026 and rs11805303 with the in-
cidence of cGVHD were found (data not shown).
In multivariate analysis, along with aGVHD, the
donor genotype at rs2301436 and rs3093023 remained
significantly associated with the incidence of cGVHD.
Interestingly, the GG genotype versus the AA and AG
genotypes in donors showed a protective effect for
rs2301436 (odds ratio [OR]: 0.16; 95% confidence in-
terval [CI]: 0.05-0.51; P 5 .002), as well as for
rs3093023 (OR: 0.24; 95% CI: 0.09-0.65; P 5 .005)
(Table 4). In contrast, the influence of female to
maleHSCTwas not significant inmultivariate analysis
(P 5 .37). These data indicate that the GG donor ge-
notype at tagSNP rs2301436 and SNP rs3093023 in
the CCR6 region is protective for cGVHD.
TRM, Relapse, and OS Were Not Significantly
Influenced by the Polymorphisms Studied
The median follow-up was 68 months (range,
8-157 months) for surviving patients and 8 monthsnd IFD at Day 100: Univariate and Multivariate Analyses
Univariate Multivariate
OR P Value OR P Value
9 (0.06-0.58) .004 0.16 (0.05-0.51) .002
6 (1.32-6.16) .007 2.23 (0.97-5.42) .06
1 (2.12-0.76) .02 0.24 (0.09-0.65) .005
2 (1.37-6.49) .02 3.02 (0.09-0.65) .01
0 (2.07-9.77) .0001 4.69 (2.00-10.95) .0004
8 (0.70-3.52) .27 1.54 (0.60-3.93) .37
1 (1.00-4.88) .05 1.88 (0.74-4.76) .18
8 (0.16-0.87) .02 0.26 (0.10-0.68) .006
4 (0.30-1.35) .24 0.34 (0.14-0.86) .02
7 (2.5-12.07) .0004 4.86 (1.73-13.62) .003
9 (0.24-1.04) .06 0.49 (0.20-1.23) .13
0 (1.10-6.13) .03 3.59 (1.41-11.25) .008
8 (0.88-5.40) .09 2.15 (0.89-5.36) .01
8 (0.86-5.01) .10 2.41 (0.89-6.53) .08
7 (0.90-11.24) .07 3.32 (0.86-12.78) .08
6 (0.16-3.70) .73 0.46 (0.08-2.64) .38
Figure 1. Influence of genotype of rs2301436 and rs3093023 on the
incidence of chronic GVHD. (A) Recipients receiving a stem cell graft
from a homozygous donor for rs2301436 (ie, genotyped as GG) showed
a significantly lower incidence of chronic GVHD (P 5 .004, univariate
analysis; P 5 .002, multivariate analysis). (B) Recipients genotyped as
AG showed a higher incidence of chronic GVHD (P 5 .007, univariate
analysis; P 5 .06, multivariate analysis). (C) Recipients receiving a stem
cell graft from a homozygous donor for rs3093023 (ie, genotyped as
GG) showed a significantly lower incidence of chronic GVHD (P 5
.01, univariate analysis; P 5 .005, multivariate analysis). (D) Recipients
genotyped as AG showed a higher incidence of chronic GVHD (P 5
.006, univariate analysis; P 5 .01, multivariate analysis).
Figure 2. Cumulative incidence of IFD at day 100. Donor GG genotype
at CCR6 tagSNP rs2301436 was associated with a higher incidence of
IFD (dashed line) compared with AA and AG genotypes (black line)
(P 5 .003, log-rank test).
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lapse, including molecular, genetic, and hematologic
relapse, occurred in 54 of 154 evaluable patients
(35%). Known risk factors for relapse were significant
in our multivariate analysis, with a diagnosis of chronic
myelogenous leukemia, absence of cGVHD, and lack
of prophylactic donor lymphocyte infusion increasing
the risk of relapse (Table 4). Recipient genotype at
CCR6 tagSNP rs2301436 was associated with the inci-
dence of relapse (AA, 50%; AG, 27%; GG, 38%;
P 5 .05 for AA vs AG/GG); however, this association
was not significant on multivariate analysis (Table 4).No effects were observed for any of the other SNPs
tested.
Relapse-free survival andOS at 5 years were 37.5%
and 55%, respectively, and 1-year TRM was 21%.
None of the investigated SNPs showed any association
with these outcome parameters.
Donor GG Genotype at rs2301436 Influences
the Occurrence of IFD
The incidences of candidemia and invasive mold
infections at 100 days were 10% and 7.5%, respec-
tively (Table 1). The GG genotype at rs2301436 in
donors was associated with a higher incidence of
IFD (32%) as opposed to AA (12%) and AG (16%)
(P 5 .03, GG vs AA/AG) (Table 4 and Figure 2). In
multivariate analysis, donor rs2301436 genotype was
the only significant risk factor, although the presence
of aGVHD and an idarubicin-containing conditioning
regimen both showed a trend toward more IFD (Table
4). Donor rs3093023 GG genotype was accompanied
by an increased incidence of IFD, but this was not sta-
tistically significant (24% vs 15% for AA and 12% for
AG; P 5 .22). In a previous study, we determined the
gene status of the dectin-1 polymorphism Y238X,
which is known to influence Candida colonization
and possibly invasive aspergillosis in HSCT recipients
[29-31]; however, we found no association between the
dectin-1 genotype and IFD at day 100. These data sug-
gest that theGG genotype atCCR6 tagSNP rs2301436
influences posttransplantation immunity against fun-
gal infections.
We also evaluated the association with Gram-
positive bacteremia for all 4 tested SNPs and found
none. Data on cytomegalovirus and Epstein-Barr virus
reactivation were incomplete and insufficient to per-
form proper statistical analysis, although Epstein-
Barr virus reactivation apparently was not influenced
by any of the SNPs.DISCUSSION
The role of polymorphisms in non-HLA genes in
the outcome of allogeneic HSCT is a subject that has
1448 Biol Blood Marrow Transplant 17:1443-1449, 2011K. Broen et al.received much attention in the last few years. The par-
ticular focus here is on SNPs in genes involved in the
immune system. However, with few exceptions, a gen-
eral problem with genetic association studies is that
documented associations are very context-dependent
and thus often difficult to confirm and reproduce.
This also seems to apply to the rs11209026 IL-23R
polymorphism; a previous large study failed to confirm
an impact on GVHD in the particular setting of unre-
lated donor HSCT [32]. In the present study, we were
not able to reproduce the repeatedly described protec-
tion against aGVHD of the donor GA genotype at
SNP rs11209026 [17-19]. This GA genotype,
resulting in Arg381Gln, is believed to perturb the IL-
23 receptor function, reducing alloreactive T cell re-
sponses that mediate aGVHD. We believe that we
could not confirm this genetic association mainly be-
cause of the practice of ex vivo T cell depletion in all
of our transplants, as opposed to Elmaagacli et al.
[17], who did not perform any T cell depletion. The al-
lele frequency was comparable in the 2 studies (A allele
frequency z 6%), but the incidence of GVHD was
lower in our study, which is directly related to the use
of T cell–depleted stem cell grafts. T cell depletion
most likely results in delayed T cell recovery, which
might influence the pathogenesis of aGVHD. Altering
the kinetics and reducing the impact of T cell function
might alter the influence genetic variations, such as
those in the IL-23/Th17, pathway as well. Context
dependency is a recurring theme in studies on genetic
associations, anddiscrepancies are often found, empha-
sizing the need for caution when generalizing results
from previous association studies.
Studying a second gene prominent in the IL-23/
Th17 pathway, the chemokine receptor CCR6, we
found significant associations between donor geno-
type at rs2301436 and rs3093023 and the occurrence
of cGVHD. For rs2301436, the incidence of IFD
was increased significantly, whereas for rs3093023,
only a trend toward a higher incidence was seen. The
GG genotype of rs2301436 was protective for
cGVHD, but conferred a high risk for developing
IFD. SNP rs2301436 is considered a tagSNP for the
CCR6 gene, but the SNP itself lies within the
FGFR10P gene [22]. Functional consequences of the
SNP itself, and of the CCR6 phenotype corresponding
with the tagSNP, are not yet completely known. How-
ever, the A allele of rs2301436 recently has been asso-
ciated with a modestly increased risk for both Crohn’s
disease and rheumatoid arthritis, with a protective ef-
fect attributed to the G allele [23]. Kochi et al. [22]
showed that two different polymorphisms, both lo-
cated within the CCR6 gene and in linkage disequilib-
rium with tagSNP rs2301436, regulate the expression
of CCR6. Therefore, we tested the impact of one of
these polymorphisms, SNP rs3093023, on the clinical
outcome after allogeneic HSCT and also observeda protective effect of the G allele. Although no direct
functional consequences for these specific CCR6-
associated polymorphisms are known, functional
studies of other polymorphisms in strong linkage dis-
equilibriumwith rs3093023 have shown that a triallelic
dinucleotide polymorphism correlates with CCR6 ex-
pression levels as well as with the presence of IL-17 in
patients with rheumatoid arthritis [22]. In the absence
of data on any functional consequences from the geno-
type of tagSNP rs2301436 or SNP rs3093023 regard-
ing CCR6, we propose 2 general hypotheses that are
not mutually exclusive. One hypothesis is that the
GG genotype at CCR6 SNPs rs2301436 and
rs3093023 might represent the normal CCR6 variant,
as opposed to what might be the dysfunctional A allele.
Kochi et al. [22] reported that in activated cells, expres-
sion levels of CCR6 increased with the number
T alleles. Normal CCR6 levels are associated with
normal functioning APCs and thus contribute to intact
mucosal immune homeostasis [33]. Because distorted
immune homeostasis predisposes to GVHD [34], the
GG genotype could decrease the risk of excessive in-
flammation. In addition, normal CCR6-mediated
Th17 homing might result in impaired Th1 responses,
with decreased alloreactivity and tissue damage pro-
tecting subjects from GVHD [8], and decreased
Th1-mediated antifungal defenses, resulting in more
infections [35,36]. This hypothesis relies strongly on
the assumption that Th1 cells are more important to
the onset of cGVHD than Th17 cells.
An alternative hypothesis could be that the GG ge-
notype at the CCR6 SNPs might correspond to low
levels of the CCR6 protein, impairing homing of
APCs and Th17 cells to GVHD target tissues and in-
fection sites, as well as to T cell priming sites [37]. Re-
duced APC function results in reduced alloreactive
T cell responses and GVHD, along with an increased
risk of fungal infections due to less effective phagocyte
recruitment [38]. Alternatively, reduced Th17 homing
might reduce GVHD, given that a role for Th17 in hu-
mans has been suggested [39]. In addition, impaired
Th17 responses might perturb host antifungal de-
fenses, increasing the risk for IFD [40]. This hypothe-
sis strongly relies on the assumption of an important,
but as-yet unconfirmed, role for Th17 in human
SCT and cGVHD and IFD.
The present study is the first to show an association
with the donor genotype of the CCR6 tagSNP
rs2301436 and the occurrence of cGVHD and IFD,
as well as an association with the donor genotype of
the CCR6 SNP rs3093023, and we believe that our
findings provide new directions for further research.
We conclude that patients undergoing allogeneic
HSCT might benefit from typing for these particular
SNPs when searching for a suitable stem cell donor, al-
though further research on CCR6 gene variation is
needed.
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